H.R. 938 · 116th Congress
BLOCKING Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SchraderSponsor16 cosponsors · 13 D, 3 R
R
Carter
AC
D
Craig
DD
D
Dingell
AE
D
Eshoo
FP
D
Pallone
RR
D
Ruiz
JK
D
Kennedy
DM
D
Matsui
BR
D
Rush
JV
D
Van Drew
YC
D
Clarke
JS
D
Schakowsky
GW
R
Walden
BM
D
McAdams
DM
D
Mucarsel-Powell
MM
R
Meadows1 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 or the BLOCKING Act of 2019
What it does: CRS summary · Reported to House · May 2, 2019
Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 or the BLOCKING Act of 2019
This bill modifies provisions related to market exclusivity for a generic drug.
Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug.
The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, and (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: BLOCKING Act of 2019
Also known as: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019
Latest action (May 2, 2019): Placed on the Union Calendar, Calendar No. 24.
Policy area: Health · Origin: House · Introduced: Jan 31, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.